Results 41 to 50 of about 622,361 (248)

The new pneumococcal vaccine [PDF]

Clinical Microbiology and Infection, 2002
Pneumococcal disease is now the leading cause of vaccine-preventable bacterial disease in children worldwide. Although a pneumococcal polysaccharide vaccine has been available for over three decades, its use has been limited due to poor immunogenicity in the most vulnerable children, aged less than 2 years.
openaire   +3 more sources

Molecular surveillance of nasopharyngeal carriage of Streptococcus pneumoniae in children vaccinated with conjugated polysaccharide pneumococcal vaccines

Scientific Reports, 2016
Following the introduction of pneumococcal conjugate vaccines (PCVs) for infants, surveillance studies on Streptococcus pneumoniae carriage have proven valuable for monitoring vaccine effects.
A. Wyllie, A. Wijmenga-Monsuur, M. V. van Houten, A. A. Bosch, James A. Groot, Jody van Engelsdorp Gastelaars, J. Bruin, D. Bogaert, N. Rots, E. Sanders, K. Trzciński   +10 more
semanticscholar   +1 more source

Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023

MMWR Recommendations and Reports, 2023
Summary This report compiles and summarizes all published recommendations from CDC’s Advisory Committee on Immunization Practices (ACIP) for use of pneumococcal vaccines in adults aged ≥19 years in the United States. This report also includes updated and
Miwako Kobayashi, T. Pilishvili, Jennifer L. Farrar, A. Leidner, R. Gierke, Namrata Prasad, Pedro Moro, Doug Campos-Outcalt, Rebecca L Morgan, Sarah S. Long, K. Poehling, Adam L. Cohen   +11 more
semanticscholar   +1 more source

Adult indication 13-valent pneumococcal conjugate vaccine clinical development overview: formulation, safety, immunogenicity (dosing and sequence), coadministration, and efficacy

Expert Review of Vaccines
Introduction There was no 13-valent pneumococcal conjugate vaccine (PCV13) adult antibody concentration threshold regulatory criterion for licensure – unlike the pediatric indication; consequently, for the adult indication, PCV13 serotype-specific ...
Mark A. Fletcher, Beate Schmoele-Thoma, Jelena Vojicic, Derek Daigle, Peter R. Paradiso, Graciela del Carmen Morales   +5 more
doaj   +1 more source

Socioeconomic determinants of vaccination against pneumococcus in 763 945 patients with heart failure

ESC Heart Failure, EarlyView.
Respiratory infections heighten risks for heart failure (HF) patients, yet 2020 data from France show low vaccination rates: 12.6% for pneumococcus and 63.1% for influenza. Using logistic regression on 763,945 HF patients, older age, female sex, and social deprivation were associated with lower pneumococcus vaccination, despite frequent healthcare ...
F. Roubille, B. Wyplosz, J. Fernandes, B. Grenier, F. Raguideau, E. Blanc, G. Goussiaume   +6 more
wiley   +1 more source

Next-Generation Whole-Cell Pneumococcal Vaccine

Vaccines, 2019
Streptococcus pneumoniae remains a major public health hazard. Although Pneumococcal Conjugate Vaccines (PCVs) are available and have significantly reduced the rate of invasive pneumococcal diseases, there is still a need for new vaccines with unlimited ...
Victor Morais, Esther Texeira, Norma Suarez   +2 more
doaj   +1 more source

Cancer in pregnancy: FIGO Best practice advice and narrative review

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Cancer during pregnancy is relatively rare. The incidence is underestimated due to the lack of international registries covering both high‐income and low‐ and middle‐income countries, and is expected to rise with increasing maternal age and increasing global adoption of cell‐free DNA testing for aneuploidy.
Surabhi Nanda, Melanie Nana, Long Nguyen‐Hoang, Sumaiya Adam, Fionnuala McAuliffe, Lina Bergman, Sarikapan Wilailak, Orla McNally, Cynthia V. Maxwell, Nikhil Purandare, Bo Jacobsson, Virna P. Medina, Anil Kapur, Titus Beyuo, Francisco Ruiloba, Ernesto Castelazo, Graeme N. Smith, Sharleen L. O'Reilly, Patrick O'Brien, Mark Hanson, Mary L. Rosser, Claudio Sosa, Valerie Guinto, Jonathan Berek, Catherine Nelson‐Piercy, Frédéric Amant, Liona Poon, on behalf of the FIGO Committee on the Impact of Pregnancy on Long‐term Health, FIGO Committee on Women's Cancer, and the FIGO Division of Maternal and Newborn Health   +29 more
wiley   +1 more source

Pneumococcal vaccine for asthma

Cochrane Database of Systematic Reviews, 2002
Infection with Streptococcus pneumoniae is an important cause of pneumonia and other serious illnesses, particularly amongst those with certain high-risk medical conditions such as asthma. Although pneumococcal vaccine is routinely advocated for people with asthma, there is uncertainty about the evidence base that underpins this recommendation.To ...
Aziz Sheikh, Sangeeta Dhami, Bernadette Alves   +2 more
openaire   +5 more sources

Prevention of Community-Acquired Pneumonia with Available Pneumococcal Vaccines

International Journal of Molecular Sciences, 2016
Community-acquired pneumonia (CAP) places a considerable burden on society. A substantial number of pediatric and adult CAP cases are due to Streptococcus pneumoniae, but fortunately there are effective vaccines available that have a significant impact ...
N. Principi, S. Esposito
semanticscholar   +1 more source

Optimising Vaccination Status in a Belgian Dermatological Immune‐Mediated Inflammatory Disease Population: An Education‐Based Pro‐Active Patient‐Centred Approach

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Patients with dermatological immune mediated inflammatory diseases (IMIDs) are increasingly treated with immunosuppressive and ‐modulating drugs. Some of these drugs increase the risk of acquiring infections and more complications can arise during an infection while treated with these agents.
Femke Lieten, Tine Vanhoutvin, Dorien Hunin, Céline Vanvelk, Liesbeth Gilissen, Petra De Haes, An Van Laethem, Francisca Castelijns, Tom Hillary   +8 more
wiley   +1 more source